MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$37.88
Change
+$0.50 (+1.34%)
Capitalization
10.2B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more

Industry: #Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EXEL with price predictions
Sep 05, 2025

Momentum Indicator for EXEL turns negative, indicating new downward trend

EXEL saw its Momentum Indicator move below the 0 level on August 28, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXEL's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where EXEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on August 15, 2025. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 281 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.015) is normal, around the industry mean (20.143). P/E Ratio (18.212) is within average values for comparable stocks, (52.852). Projected Growth (PEG Ratio) (2.598) is also within normal values, averaging (2.088). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.916) is also within normal values, averaging (327.233).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 9.05% to 68 cents per share on November 04

Exelixis EXEL Stock Earnings Reports
Q3'25
Est.
$0.68
Q2'25
Beat
by $0.11
Q1'25
Beat
by $0.25
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.13
The last earnings report on July 28 showed earnings per share of 75 cents, beating the estimate of 63 cents. With 2.52M shares outstanding, the current market capitalization sits at 10.20B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PRAY31.230.03
+0.11%
FIS Christian Stock ETF
USTB51.100.05
+0.10%
VictoryShares Short-Term Bond ETF
LST38.470.01
+0.02%
Leuthold Select Industries ETF
EFRA34.36N/A
N/A
iShares Environmental Infras & IndstrETF
AMZY15.28-0.17
-1.10%
YieldMax AMZN Option Income Strategy ETF

EXEL and Stocks

Correlation & Price change

A.I.dvisor tells us that EXEL and LQDA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and LQDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.34%
LQDA - EXEL
31%
Poorly correlated
+0.03%
JAZZ - EXEL
30%
Poorly correlated
+1.16%
RIGL - EXEL
29%
Poorly correlated
+3.02%
ACLX - EXEL
29%
Poorly correlated
+0.64%
ADCT - EXEL
29%
Poorly correlated
+4.12%
More